Risperidone for Schizophrenia (DLP-114 Trial)

"This trial is no longer open for recruitment. It was first posted on April 1st 2021 and the last update occurred November 27th 2022. If you are looking to participate in another clinical study, there exist 333 trials searching for patients with schizophrenia and 17 studies specifically seeking out enrolment of those using Risperidone as treatment."

"According to the research sponsor, Delpor, Inc., this trial's primary metric will be Local Tolerance over a period of 6-12 months. Additionally, there are three secondary metrics that need to be monitored: Implant device placement depth (measured via ultrasound), Implant Pharmacokinetic Profile (blood plasma concentration of risperidone and 9-OH risperidone following implantation) and Oral Pharmacokinetic Profile (blood plasma measurements taken after oral administration)."

"Most widely used to address acute coryza, risperidone has also been seen as a viable treatment for multiple other ailments such as autistic disorder, bipolar disorder and irritability."

"The requirements for inclusion in this trial state that potential participants must be aged 18 or above and under 70 years old."

"Risperidone was initially investigated in 2004 at the Psychiatric Service of Tel-Aviv Sourasky Medical Center. 205 associated clinical trials have been conducted to date, with 17 live studies as of now; many occurring near Miami Lakes, Florida."

"This clinical trial is enrolling 30 people with schizophrenia aged between 18 and 70. Core inclusion criteria include: diagnosis of DSM-V defined schizophrenia or schizoaffective disorder, stable oral risperidone 2mg to 3mg for two weeks prior, written informed consent from the patient/legal representative, outpatient status as evidenced by PANSS Total Score ≤ 80 at screening and CGI-I-S ≤ 4 (moderately ill), C-SSRS score type of 4 - 5 requiring evaluation for safety purposes if present, BMI within 18.5 to 40.0 kg/m2 range, suitable venous access for blood sampling"

"This trial is no longer active and applications are not being accepted. The study was originally posted on April 1, 2021 with its last update made on November 27th 2022. For those looking for alternative trials, there are 333 clinical studies involving schizophrenia currently recruiting patients and 17 investigations concerning Risperidone that have open enrollment slots available."